摘要
目的观察小剂量多西他赛单药治疗老年晚期非小细胞肺癌(NSCLC)的疗效和不良反应。方法 46例老年NSCLC(Ⅲ～Ⅳ期)患者均经病理学或细胞学检查确诊。应用江苏恒瑞生产多西他赛(艾素)35mg/m2,1次/周,连用6周,休息两周为1周期,两周期后评价疗效。结果 46例患者均可评价疗效,CR 1例,PR 11例,有效率26.0%,中位生存期8.3个月,中位疾病进展时间(TTP)7.2个月,1年生存率45.5%。主要不良反应为白细胞减少和过敏反应,均可耐受。结论小剂量多西他赛单药治疗老年晚期NSCLC疗效确切,可改善老年患者生存质量,延长生存期,不良反应轻。
Objective To observe the efficacy,clinical benefit response and related toxicity of docetaxel lower-agent in the treatment of elderly patients with advanced non-small cell lung cancer（NSCLC）.Methods 46 elderly patients with histologically or cytologically diagnosed advanced NSCLC were treated with docetaxel（at a lower dose of 35mg/m2 infused on day 1 every week.6 weeks as one cycle）.Between 2 cycles,There was 2 weeks′ rest.Results The response rates of docetaxel group was 26.0%.The medium duration of response was 8.3 months.medium time to tumor progression was 7.2 months.1 year survival rate 45.5%.one case was CR,and 11cases were PR.Conclusion The toxicity of docetaxel was mild and no one needs to stop the medicine.Docetaxel lower-agent is an effective drug in the treatment of elderly patients with advanced NSCLC.It can improve the quality of life.The toxicity is acceptable.
出处
《实用心脑肺血管病杂志》
2011年第7期1124-1125,共2页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
关键词
非小细胞肺癌
多西他赛
药物疗法
Non-small cell lung cancer
Docetaxel
Drug therapy
